Anna Scomparin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Scomparin has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Ronit Satchi-Fainaro
Tel Aviv University
30 shared publications Adva Krivitsky
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Room 607, Tel Aviv University, Tel Aviv, Israel
7 shared publicationsDina Polyak
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Room 607, Tel Aviv University, Tel Aviv, Israel
7 shared publications- Galia Tiram
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
7 shared publications - Helena F. Florindo
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal
7 shared publications Anat Eldar-Boock
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
6 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (11) , 17354-17365
Exploiting Greener Formulations of Benzalkonium Chloride with Enhanced Antibacterial Properties
In recent years, the extensive use of benzalkonium chloride (BKC) as a disinfectant has raised significant concerns due to its toxicity and its potential to promote environmental impact and antimicrobial resistance. In order to reduce the toxicity associated with BKC in spray disinfectants, the antimicrobial agent was coencapsulated into vesicle-like nanosystems, known as nanodroplets (NDs), with limonene, a natural essential oil renowned for its antimicrobial properties and commonly used in cleaning product formulations. The aim was to reduce the required concentration of BKC in the disinfectant formulation by enhancing its antimicrobial activity through encapsulation in nanodroplets (BKC-NDs) and by loading limonene within the core of the nanodroplets. The vesicles consist of two distinct phases: an organic core composed of decafluoropentane and limonene and an outer aqueous shell stabilized at the interface by BKC. In this formulation, therefore, BKC plays both a functional role as an antimicrobial agent and a technological role as a surfactant, allowing for the formation of the NDs. Moreover, a more sustainable formulation was obtained by removing decafluoropentane and retaining limonene in the vesicle core. A library of BKC-NDs with varying BKC concentrations (0.008, 0.08, and 2.4% w/v), with or without a decafluoropentane core, was prepared to finally select the minimum concentration with the highest antimicrobial activity. BKC-NDs demonstrated superior antimicrobial properties compared to BKC in aqueous solution against Staphylococcus aureus and Escherichia coli and, in particular, the formulation at 0.08% w/v, while maintaining comparable in vitro biocompatibility. The efficiency of BKC-NDs spray disinfectants was also assessed from a physicochemical perspective, demonstrating high wettability, wide spray angle, and long-term stability upon storage while retaining antimicrobial efficacy. A novel green spray disinfectant based on BKC, which exploits materials of natural origin to reduce the concentration of chemicals, was developed to minimize its related toxicity and environmental contamination.
- 11 March 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (11) , 17354-17365
Open AccessExploiting Greener Formulations of Benzalkonium Chloride with Enhanced Antibacterial Properties
In recent years, the extensive use of benzalkonium chloride (BKC) as a disinfectant has raised significant concerns due to its toxicity and its potential to promote environmental impact and antimicrobial resistance. In order to reduce the toxicity associated with BKC in spray disinfectants, the antimicrobial agent was coencapsulated into vesicle-like nanosystems, known as nanodroplets (NDs), with limonene, a natural essential oil renowned for its antimicrobial properties and commonly used in cleaning product formulations. The aim was to reduce the required concentration of BKC in the disinfectant formulation by enhancing its antimicrobial activity through encapsulation in nanodroplets (BKC-NDs) and by loading limonene within the core of the nanodroplets. The vesicles consist of two distinct phases: an organic core composed of decafluoropentane and limonene and an outer aqueous shell stabilized at the interface by BKC. In this formulation, therefore, BKC plays both a functional role as an antimicrobial agent and a technological role as a surfactant, allowing for the formation of the NDs. Moreover, a more sustainable formulation was obtained by removing decafluoropentane and retaining limonene in the vesicle core. A library of BKC-NDs with varying BKC concentrations (0.008, 0.08, and 2.4% w/v), with or without a decafluoropentane core, was prepared to finally select the minimum concentration with the highest antimicrobial activity. BKC-NDs demonstrated superior antimicrobial properties compared to BKC in aqueous solution against Staphylococcus aureus and Escherichia coli and, in particular, the formulation at 0.08% w/v, while maintaining comparable in vitro biocompatibility. The efficiency of BKC-NDs spray disinfectants was also assessed from a physicochemical perspective, demonstrating high wettability, wide spray angle, and long-term stability upon storage while retaining antimicrobial efficacy. A novel green spray disinfectant based on BKC, which exploits materials of natural origin to reduce the concentration of chemicals, was developed to minimize its related toxicity and environmental contamination.
- Open Access
- 5 October 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 371, 124499
Exploring new buccal films based on hydroxyethyl cellulose and Linecaps® combination for the pediatric delivery of hydrophobic molecules
- 5 October 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 371, 124499
Open AccessExploring new buccal films based on hydroxyethyl cellulose and Linecaps® combination for the pediatric delivery of hydrophobic molecules
- Open Access
- 13 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (50) , eadr4762
Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers
Combined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their therapeutic efficacy. To circumvent this, poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–based nanoparticles were developed as a platform for the codelivery of synergistic drug ratios, improving therapeutic efficacy by increasing the percentage of injected dose reaching the tumor. Nonetheless, extravasation-dependent tumor accumulation is susceptible to variations in tumor vasculature; therefore, PLGA-PEG was modified with sulfates to actively target P-selectin–expressing cancers. Here, we show the potential of our platform in unique three-dimensional (3D) in vitro and in vivo models. The P-selectin–targeted nanoparticles showed enhanced accumulation in 3D spheroids and tissues of P-selectin–expressing BRAF-mutated melanomas and BRCA-mutated breast cancers, resulting in superior in vivo efficacy and safety. This nanoplatform could advance the codelivery of a plethora of anticancer drug combinations to various P-selectin–expressing tumors.
- 13 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (50) , eadr4762
Open AccessTwo-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers
Combined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their therapeutic efficacy. To circumvent this, poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–based nanoparticles were developed as a platform for the codelivery of synergistic drug ratios, improving therapeutic efficacy by increasing the percentage of injected dose reaching the tumor. Nonetheless, extravasation-dependent tumor accumulation is susceptible to variations in tumor vasculature; therefore, PLGA-PEG was modified with sulfates to actively target P-selectin–expressing cancers. Here, we show the potential of our platform in unique three-dimensional (3D) in vitro and in vivo models. The P-selectin–targeted nanoparticles showed enhanced accumulation in 3D spheroids and tissues of P-selectin–expressing BRAF-mutated melanomas and BRCA-mutated breast cancers, resulting in superior in vivo efficacy and safety. This nanoplatform could advance the codelivery of a plethora of anticancer drug combinations to various P-selectin–expressing tumors.
- Open Access
Concanavalin a Grafted Nanoemulsions for Nasal Delivery: Preliminary Studies with Fluorescently Labelled Formulations
Nasal delivery is a non-invasive strategy for effective drug delivery. Nevertheless, in order to promote drug uptake by the nasal mucosa, it is fundamental to increase its residence time in the administration site. To this aim, nano-sized drug delivery systems are widely exploited. Within this context, the commercially available nanoemulsion for parenteral nutrition is a biocompatible, safe and clinically approved vehicle for drug delivery. Furthermore, the nanodroplet surface can be modified via a well-established protocol to graft Concavalin A, a lectin capable of improving the mucosal adhesion, by binding to the α-mannose and α-glucose residues of the mucosal glycocalyx. The obtained targeted formulation is able to induce haemagglutination, as opposite to non-modified nanoemulsion. Furthermore, the ConA grafting maintains the physicochemical properties of the nanodroplets (size~230 nm, Z < −35 mV) and does not interfere with the loading of the Rose Bengal fluorescent probe. Fluorescently labelled ConA grafted nanodroplets showed enhanced permeation and accumulation in ex vivo bovine nasal mucosa. This study is a proof of concept that Concanavalin A can be used to decorate the surface of nanodroplets, acting as a permeation promoter.
Open AccessConcanavalin a Grafted Nanoemulsions for Nasal Delivery: Preliminary Studies with Fluorescently Labelled Formulations
Nasal delivery is a non-invasive strategy for effective drug delivery. Nevertheless, in order to promote drug uptake by the nasal mucosa, it is fundamental to increase its residence time in the administration site. To this aim, nano-sized drug delivery systems are widely exploited. Within this context, the commercially available nanoemulsion for parenteral nutrition is a biocompatible, safe and clinically approved vehicle for drug delivery. Furthermore, the nanodroplet surface can be modified via a well-established protocol to graft Concavalin A, a lectin capable of improving the mucosal adhesion, by binding to the α-mannose and α-glucose residues of the mucosal glycocalyx. The obtained targeted formulation is able to induce haemagglutination, as opposite to non-modified nanoemulsion. Furthermore, the ConA grafting maintains the physicochemical properties of the nanodroplets (size~230 nm, Z < −35 mV) and does not interfere with the loading of the Rose Bengal fluorescent probe. Fluorescently labelled ConA grafted nanodroplets showed enhanced permeation and accumulation in ex vivo bovine nasal mucosa. This study is a proof of concept that Concanavalin A can be used to decorate the surface of nanodroplets, acting as a permeation promoter.
- Open Access
- 20 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1772
Use of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation
Chronic inflammation contributes to the pathogenesis of many diseases, including apparently unrelated conditions such as metabolic disorders, cardiovascular diseases, neurodegenerative diseases, osteoporosis, and tumors, but the use of conventional anti-inflammatory drugs to treat these diseases is generally not very effective given their adverse effects. In addition, some alternative anti-inflammatory medications, such as many natural compounds, have scarce solubility and stability, which are associated with low bioavailability. Therefore, encapsulation within nanoparticles (NPs) may represent an effective strategy to enhance the pharmacological properties of these bioactive molecules, and poly lactic-co-glycolic acid (PLGA) NPs have been widely used because of their high biocompatibility and biodegradability and possibility to finely tune erosion time, hydrophilic/hydrophobic nature, and mechanical properties by acting on the polymer’s composition and preparation technique. Many studies have been focused on the use of PLGA-NPs to deliver immunosuppressive treatments for autoimmune and allergic diseases or to elicit protective immune responses, such as in vaccination and cancer immunotherapy. By contrast, this review is focused on the use of PLGA NPs in preclinical in vivo models of other diseases in which a key role is played by chronic inflammation or unbalance between the protective and reparative phases of inflammation, with a particular focus on intestinal bowel disease; cardiovascular, neurodegenerative, osteoarticular, and ocular diseases; and wound healing.
- 20 June 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1772
Open AccessUse of Poly Lactic-co-glycolic Acid Nano and Micro Particles in the Delivery of Drugs Modulating Different Phases of Inflammation
Chronic inflammation contributes to the pathogenesis of many diseases, including apparently unrelated conditions such as metabolic disorders, cardiovascular diseases, neurodegenerative diseases, osteoporosis, and tumors, but the use of conventional anti-inflammatory drugs to treat these diseases is generally not very effective given their adverse effects. In addition, some alternative anti-inflammatory medications, such as many natural compounds, have scarce solubility and stability, which are associated with low bioavailability. Therefore, encapsulation within nanoparticles (NPs) may represent an effective strategy to enhance the pharmacological properties of these bioactive molecules, and poly lactic-co-glycolic acid (PLGA) NPs have been widely used because of their high biocompatibility and biodegradability and possibility to finely tune erosion time, hydrophilic/hydrophobic nature, and mechanical properties by acting on the polymer’s composition and preparation technique. Many studies have been focused on the use of PLGA-NPs to deliver immunosuppressive treatments for autoimmune and allergic diseases or to elicit protective immune responses, such as in vaccination and cancer immunotherapy. By contrast, this review is focused on the use of PLGA NPs in preclinical in vivo models of other diseases in which a key role is played by chronic inflammation or unbalance between the protective and reparative phases of inflammation, with a particular focus on intestinal bowel disease; cardiovascular, neurodegenerative, osteoarticular, and ocular diseases; and wound healing.
- 12 April 2023
- Published by Springer Nature
- p. 597-629
Cyclodextrins and Cyclodextrin-Based Nanosponges for Anti-Cancer Drug and Nutraceutical Delivery
- 12 April 2023
- Published by Springer Nature
- p. 597-629
Cyclodextrins and Cyclodextrin-Based Nanosponges for Anti-Cancer Drug and Nutraceutical Delivery
- Open Access
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression
Development of resistance to chemo- and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors, among which we found that monocyte chemoattractant protein-1 (MCP-1) and its receptors, CCR2 and CCR4, were overexpressed in MBM compared with primary lesions. Among other sources of MCP-1 in the brain, we show that melanoma cells altered astrocyte secretome and evoked MCP-1 expression and secretion, which in turn induced CCR2 expression in melanoma cells, enhancing in vitro tumorigenic properties, such as proliferation, migration, and invasion of melanoma cells. In vivo pharmacological blockade of MCP-1 or molecular knockout of CCR2/CCR4 increased the infiltration of cytotoxic CD8 + T cells and attenuated the immunosuppressive phenotype of the BME as shown by decreased infiltration of Tregs and tumor-associated macrophages/microglia in several models of intracranially injected MBM. These in vivo strategies led to decreased MBM outgrowth and prolonged the overall survival of the mice. Our findings highlight the therapeutic potential of inhibiting interactions between BME and melanoma cells for the treatment of this disease.
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Open AccessMCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression
Development of resistance to chemo- and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors, among which we found that monocyte chemoattractant protein-1 (MCP-1) and its receptors, CCR2 and CCR4, were overexpressed in MBM compared with primary lesions. Among other sources of MCP-1 in the brain, we show that melanoma cells altered astrocyte secretome and evoked MCP-1 expression and secretion, which in turn induced CCR2 expression in melanoma cells, enhancing in vitro tumorigenic properties, such as proliferation, migration, and invasion of melanoma cells. In vivo pharmacological blockade of MCP-1 or molecular knockout of CCR2/CCR4 increased the infiltration of cytotoxic CD8 + T cells and attenuated the immunosuppressive phenotype of the BME as shown by decreased infiltration of Tregs and tumor-associated macrophages/microglia in several models of intracranially injected MBM. These in vivo strategies led to decreased MBM outgrowth and prolonged the overall survival of the mice. Our findings highlight the therapeutic potential of inhibiting interactions between BME and melanoma cells for the treatment of this disease.
- Open Access
- 20 May 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (5) , 1007
Lipid-Coated Nanocrystals as a Tool for Improving the Antioxidant Activity of Resveratrol
Trans-resveratrol, a polyphenolic phytoalexin found in various plant sources, has been the focus of increasing attention in recent years because of its role in the prevention of many human diseases, and particularly because of its antioxidant properties. However, the in vivo effect of trans-resveratrol after oral administration is negligible when compared to its efficacy in vitro, due to its low bioavailability. Moreover, it presents stability issues as it is an extremely photosensitive compound when exposed to light. This work aims to develop lipid-coated nanocrystals in order to improve the antioxidant activity and bioavailability of trans-resveratrol. Lipid-coated trans-resveratrol nanocrystals with sizes lower than 500 nm, spherical shapes and smooth surfaces were obtained via a milling method. They showed a faster dissolution rate than the coarse trans-resveratrol powder. The antioxidant properties of trans-resveratrol were not impaired by the milling process. The in vivo pharmacokinetics of lipid-coated trans-resveratrol nanocrystals were evaluated after oral administration to rats, with a commercial Phytosome® formulation being used for comparison purposes. An increase in the trans-resveratrol area under the curve was observed and the lipid-coated nanocrystal formulation led to an enhancement in the oral bioavailability of the compound.
- 20 May 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (5) , 1007
Open AccessLipid-Coated Nanocrystals as a Tool for Improving the Antioxidant Activity of Resveratrol
Trans-resveratrol, a polyphenolic phytoalexin found in various plant sources, has been the focus of increasing attention in recent years because of its role in the prevention of many human diseases, and particularly because of its antioxidant properties. However, the in vivo effect of trans-resveratrol after oral administration is negligible when compared to its efficacy in vitro, due to its low bioavailability. Moreover, it presents stability issues as it is an extremely photosensitive compound when exposed to light. This work aims to develop lipid-coated nanocrystals in order to improve the antioxidant activity and bioavailability of trans-resveratrol. Lipid-coated trans-resveratrol nanocrystals with sizes lower than 500 nm, spherical shapes and smooth surfaces were obtained via a milling method. They showed a faster dissolution rate than the coarse trans-resveratrol powder. The antioxidant properties of trans-resveratrol were not impaired by the milling process. The in vivo pharmacokinetics of lipid-coated trans-resveratrol nanocrystals were evaluated after oral administration to rats, with a commercial Phytosome® formulation being used for comparison purposes. An increase in the trans-resveratrol area under the curve was observed and the lipid-coated nanocrystal formulation led to an enhancement in the oral bioavailability of the compound.
- Open Access
- 4 October 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1617
Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape
Cutaneous melanoma is one of the most aggressive solid tumors, with a low survival for the metastatic stage. Currently, clinical melanoma treatments include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. Of note, innovative therapeutic regimens concern the administration of multitarget drugs in tandem, in order to improve therapeutic efficacy. However, also, if this drug combination is clinically relevant, the patient’s response is not yet optimal. In this scenario, nanotechnology-based delivery systems can play a crucial role in the clinical treatment of advanced melanoma. In fact, their nano-features enable targeted drug delivery at a cellular level by overcoming biological barriers. Various nanomedicines have been proposed for the treatment of cutaneous melanoma, and a relevant number of them are undergoing clinical trials. In Italy, researchers are focusing on the pharmaceutical development of nanoformulations for malignant melanoma therapy. The present review reports an overview of the main melanoma-addressed nanomedicines currently under study in Italy, alongside the state of the art of melanoma therapy. Moreover, the latest Italian advances concerning the pre-clinical evaluation of nanomedicines for melanoma are described.
- 4 October 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1617
Open AccessNanotechnology Addressing Cutaneous Melanoma: The Italian Landscape
Cutaneous melanoma is one of the most aggressive solid tumors, with a low survival for the metastatic stage. Currently, clinical melanoma treatments include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. Of note, innovative therapeutic regimens concern the administration of multitarget drugs in tandem, in order to improve therapeutic efficacy. However, also, if this drug combination is clinically relevant, the patient’s response is not yet optimal. In this scenario, nanotechnology-based delivery systems can play a crucial role in the clinical treatment of advanced melanoma. In fact, their nano-features enable targeted drug delivery at a cellular level by overcoming biological barriers. Various nanomedicines have been proposed for the treatment of cutaneous melanoma, and a relevant number of them are undergoing clinical trials. In Italy, researchers are focusing on the pharmaceutical development of nanoformulations for malignant melanoma therapy. The present review reports an overview of the main melanoma-addressed nanomedicines currently under study in Italy, alongside the state of the art of melanoma therapy. Moreover, the latest Italian advances concerning the pre-clinical evaluation of nanomedicines for melanoma are described.
- 1 November 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 590, 119888
Nanosponges as protein delivery systems: Insulin, a case study
- 1 November 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 590, 119888
Nanosponges as protein delivery systems: Insulin, a case study